Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
1997 ◽
Vol 41
(12)
◽
pp. 2793-2796
◽
Keyword(s):
This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease.
2019 ◽
Vol 81
(4)
◽
pp. AB441
Keyword(s):
Keyword(s):
2019 ◽
Vol 85
(6)
◽
pp. 1239-1246
◽
2012 ◽
Vol 28
(3)
◽
pp. 251-258
◽
2006 ◽
Vol 102
(4)
◽
pp. 405-412
◽
2006 ◽
Vol 11
(1)
◽
pp. 72-76
◽
Keyword(s):
2010 ◽
Vol 62
(3)
◽
pp. AB41
Keyword(s):
2012 ◽
Vol 38
(7pt2)
◽
pp. 1193-1205
◽
Keyword(s):